Rekombinanter EGFR (Cetuximab Biosimilar) Antikörper

Produktnummer ABIN7795079

Dieser Maus Monoklonal Antikörper erkennt spezifisch EGFR (Cetuximab Biosimilar) in FACS und in vivo. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für Rekombinanter EGFR (Cetuximab Biosimilar) Antikörper (ABIN7795079)

Target: EGFR (Cetuximab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser EGFR (Cetuximab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-EGFR (Cetuximab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Cetuximab Biosimilar, Endotoxin 0.05 EU/mg

Produktmerkmale: Cetuximab, a chimeric (mouse/human) anti-EGFR monoclonal antibody, is an EGFR inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab binds to EGFR and turns off the uncontrolled growth in cancers with EGFR mutations. Cetuximab can be used for treatment of KRAS wild type colon cancer but has little or no effect in colorectal tumors harboring a KRAS mutation. Before treatment using Erbitux, it is better to do a diagnosis using the real time PCR companion diagnostic test for KRAS, the therascreen KRAS test. There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1, HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, EGFR (epidermal growth factor receptor) located on cell surface sends a signal down the MAPK pathway that includes another protein, KRAS (also spelled K-ras). Mutations affecting EGFR and/or KRAS expression or activity could result in cancer. The mutated KRAS continuously sends a growth signal to the downstream pathway, leading to uncontrollable cell division, even if EGFR has been blocked.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: Less than 0.5 EU/mg of protein as determined by LAL method

Immunogen: Human EGFR / ErbB-1

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu EGFR (Cetuximab Biosimilar)

Target: EGFR (Cetuximab Biosimilar)

Andere Bezeichnung: Cetuximab Biosimilar

Substanzklasse: Biosimilar